Protocol Ledger

NCT04526665 · Phase III · ACTIVE NOT RECRUITING

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

Interventional Phase III clinical trial protocol NCT04526665 sponsored by Ipsen in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-24 Enrollment: 161 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04526665
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)161 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04526665
Protocol FieldVerified Registry Value
NCT IdentifierNCT04526665
Consolidated Lead SponsorIpsen
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment161 participants (ACTUAL)
Registered Start Date2020-09-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI